§ Catalog
82 peptides in the library, each with an evidence and risk grade. For educational purposes only.
Soluble activin type IIB receptor fusion protein studied for lean mass and metabolic health. One Phase I RCT showed increased lean mass in postmenopausal women; remaining evidence is preclinical. Flagged status, elevated risk.
Locally acting follistatin-based ligand trap investigated for lean mass in muscular dystrophy. Moderate evidence grade — two Phase 2 RCTs showed targeted muscle volume gains without significant functional improvement.
Fixed-dose combination of cagrilintide (amylin analogue) and semaglutide (GLP-1 RA) in late-clinical trials for obesity and metabolic health. Strong evidence from Phase 3 trials showing substantial weight reduction. Low risk.
Long-acting synthetic GHRH analogue studied for lean mass and longevity. Preliminary evidence — unapproved, elevated risk; one registered trial found, no peer-reviewed human efficacy data available.
CJC+DAC is catalogued in the Peptides Pub research index, with coverage focused on Lean mass.
DEGARELIX is catalogued in the Peptides Pub research index, with coverage focused on Lean mass.
GHRP-2 is catalogued in the Peptides Pub research index, with coverage focused on Lean mass.
GHRP-6 is catalogued in the Peptides Pub research index, with coverage focused on Lean mass.
Hexarelin is catalogued in the Peptides Pub research index, with coverage focused on Lean mass.
LEUPROLIDE ACETATE is catalogued in the Peptides Pub research index, with coverage focused on Lean mass.
OCTREOTIDE is catalogued in the Peptides Pub research index, with coverage focused on Lean mass.
Sermorelin is catalogued in the Peptides Pub research index, with coverage focused on Lean mass.
TRIPTORELIN is catalogued in the Peptides Pub research index, with coverage focused on Lean mass.